Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study

Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study

<p><b>Background</b></p> AZD2816 is a variant-adapted COVID-19 vaccine that expresses the full-length SARS-CoV-2 beta variant spike protein but is otherwise similar to AZD1222 (ChAdOx1 nCoV-19). This study aimed to evaluate the safety and immunogenicity of AZD1222 or AZD2816...

全面介绍

书目详细资料
Main Authors: Costa Clemens, SA, Jepson, B, Bhorat, QE, Ahmad, A, Akhund, T, Aley, PK, Bansal, H, Bibi, S, Kelly, EJ, Khan, M, Lambe, T, Lombaard, JJ, Matthews, S, Pipolo Milan, E, Olsson, U, Ramasamy, MN, Moura de Oliveira Paiva, MS, Seegobin, S, Shoemaker, K, Szylak, A, Villafana, T, Pollard, AJ, Green, JA
其他作者: AZD2816 Study Group
格式: Journal article
语言:English
出版: Elsevier 2024

相似书籍